Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy

Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV

Several studies have shown predictive value to monocyte counts in RA responses. UK study of 246 #RA pts showed pretreatment absolute monocyte count [ORadj 9.56; 1.61-59.86, p = 0.01) predicted bDMARD nonresponse @ 6 mos. Replicates other reports! https://t.co/GqGj8R0wq1 https://t.co/HJ7wFBoxGE

Steroids, Not JAKi, Are the Real Infection Risk Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain. https://t.co/rLpyo1UNjd https://t.co/bDfdLTEM1N

EULAR Daily Recap: Day 1 and 2 LIVE Daily Recap Day 1 & 2 – EULAR 2025 Coverage brings you the latest updates from EULAR 2025. Join Dr. Jack Cush, Dr. Mrinalini Dey, Dr. Antoni Chan, and Dr. Nelly Ziade as they discuss the biggest breakthroughs, standout sessions, and expert https://t.co/vkTo2MchsC

Using Combination csDMARDs in PsA Dr. Eric Ruderman shares his insights on abstracts OP0093, OP0106, and POS0106, which discuss the effectiveness of combination csDMARD therapy, long-term outcomes of methotrexate and leflunomide, and a real-world treat-to-target strategy in https://t.co/Pv4YEyYShm

Social Determinants of Health in SLE SDH, such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, https://t.co/Xf2bR7ap5m

Jokes Aside: The Impact of Laughter in RA Dr. Aurelie Najm reports on POS0685, 'The Impact of Social Frailty and Physical Function on Laughter Frequency in Rheumatoid Arthritis Patients from a Multicenter Observational Study (T-FLAG)', presented at EULAR 2025 in Barcelona, https://t.co/z3tvqQmH96

Seronegative Arthritis Breakthroughs Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb

Safety of Recombinant Zoster Vaccine in Rheumatic Patients New work presented at EULAR focuses on the RZV, which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory https://t.co/NS3h9CdGIU

Cancer risk in rheumatoid arthritis: anything new? There is still a question I have a hard time answering with certainty when people living with rheumatoid arthritis ask me: Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many https://t.co/6rbZg5Fr2k

EULAR 2025 – Day 2 Report Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j